← Back to patent-cliff list
NEU-411
Tier C — Watch / tradeNEU-411
Neuron23™ Inc
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：LRRK2
Indications (approved)：Parkinson's disease, Parkinsonism
Regional status
US
Phase II
2025-01-17
EU
Phase II
2025-01-17
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of NEU-411?
Approved indications include: Parkinson's disease, Parkinsonism.
When does the NEU-411 patent expire?
No public expiry year is available for NEU-411 yet; this page updates once verified.
How do I get a quote for NEU-411 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-01